Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
PLATTSBURGH, N.Y. — Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876.
Article content
The confidential settlement resolves the pending litigation. ' This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,' said Sanjay Goorachurn, CEO of Medisca Pharmaceutique Inc. ' We will continue to invest in more innovative products and solutions to meet our customers' evolving needs globally and ensure that new and existing customers receive the high-quality products they deserve. '
Article content
Article content
Medisca remains committed to protecting its intellectual property rights and proprietary technologies. Medisca has ongoing litigations against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of Medisca German counterpart patents. Those suits were filed in the Munich district court of Germany and request injunctions and monetary remedies.
Article content
About Medisca
Article content
Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
nVent Electric plc to Report Second Quarter 2025 Financial Results on August 1
nVent Electric plc (NYSE: NVT) ('nVent'), a global leader in electrical connection and protection solutions, will report second quarter 2025 financial results on Friday, August 1, 2025. The financial results will be posted on the company's website at The company will issue a news release when the earnings materials are publicly available, including a link to those documents. The company will also hold a conference call with analysts and investors at 9:00 a.m. ET. Related presentation materials will be posted to prior to the conference call. Conference Call and Webcast Details The call can be accessed via webcast at or by dialing 1-833-630-1071 or 1-412-317-1832. Once available, a replay of the conference call will be accessible through August 15, 2025, by dialing 1-877-344-7529 or 1-412-317-0088, along with the access code 1818589. About nVent nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world's most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at
Globe and Mail
11 minutes ago
- Globe and Mail
Keurig to Post Q2 Earnings: What Is in the Cards for Investors?
Keurig Dr Pepper Inc. KDP is scheduled to release second-quarter 2025 results on July 24, before the market opens. The company is expected to register top-line growth when it reports the quarterly results. The Zacks Consensus Estimate for quarterly revenues is pegged at $4.14 billion, indicating a 5.5% rise from the year-ago period's number. The consensus estimate for KDP's second-quarter earnings is pegged at 49 cents per share, suggesting 8.9% growth from 45 cents reported in the prior-year quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) In the last reported quarter, the company delivered an earnings surprise of 10.53%. KDP has registered an earnings surprise of 3.1%, on average, in the trailing four quarters. What the Zacks Model Unveils for KDP Stock Our proven model does not conclusively predict an earnings beat for Keurig this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that's not the case here. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Keurig has a Zacks Rank #3 at present and an Earnings ESP of -0.01%. Key Factors to Note Ahead of KDP's Q2 Results Keurig is well-positioned to deliver a strong second-quarter 2025 performance, building on the momentum of a solid first quarter. Continued brand strength, strategic pricing actions and innovation-led growth are expected to remain key drivers. The company's expansion initiatives and focus on product innovation are acting as tailwinds, while the Refreshment Beverages segment continues to show robust momentum. Additionally, the recent GHOST energy acquisition is likely to further boost results through enhanced market presence and incremental sales. In particular, the U.S. Refreshment Beverages segment is expected to remain a growth engine, led by sustained performance in the carbonated soft drinks (CSD) category. Brands like Dr Pepper, Canada Dry and 7UP are gaining share, supported by impactful innovations such as Dr Pepper Blackberry and 7UP Tropical. Emerging brands, including Electrolit and Bloom Sparkling Energy, are also gaining traction and are likely to have contributed meaningfully to second-quarter top-line growth. The GHOST acquisition has already delivered a solid start and is expected to accelerate results as integration continues. KDP's consumer-centric innovation strategy, backed by detailed scorecards measuring awareness, household penetration and loyalty, is expected to have supported continued market share gains in the quarter. The Zacks Consensus Estimate for Refreshment Beverages unit sales is pegged at $804 million, representing a year-over-year increase of 12.8%. On the international front, KDP anticipates improved growth in the second quarter, driven by late first-quarter price realization tied to inflation and the activation of stronger commercial strategies across key markets. In Mexico and Canada, momentum remains strong with brands like Penafiel, Crush and Dr Pepper, all of which benefit from strong local resonance. Continued pricing optimization and disciplined cost management are expected to have supported both top-line growth and margin expansion across international operations. However, the company continues to face inflationary pressures, particularly in its Coffee segment, which has remained sluggish for some time. The segment continues to grapple with elevated green coffee costs, reduced brewer shipments and cautious consumer spending. While KDP implemented early price increases to mitigate inflation, the uneven timing of industry-wide pricing created short-term volume and mix challenges. The Zacks Consensus Estimate for sales in the Coffee unit is $264 million, reflecting a year-over-year decline of 10.8%. Valuation Picture From a valuation perspective, Keurig stock is trading at a discount relative to historical and industry benchmarks. With a forward 12-month price-to-earnings ratio of 16.03x, which is well below the five-year high of 23.33x and the Beverages - Soft Drinks industry's average of 17.96x, the stock offers compelling value for investors seeking exposure to the sector. The recent market movements show that KDP's shares have risen 7.2% in the past six months compared with the industry's growth of 5.9%. Stocks With the Favorable Combination Here are some companies that, according to our model, have the right combination of elements to beat on earnings this reporting cycle. Anheuser-Busch InBev SA/NV BUD, aka AB InBev, currently has an Earnings ESP of +7.06% and a Zacks Rank of 3. The company is likely to register a decline in the top line when it reports second-quarter 2025 numbers. The consensus mark for revenues is pegged at $15.33 million, indicating a decline of 0.01% from the figure reported in the year-ago quarter. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for AB InBev's quarterly earnings per share is 89 cents, implying a 1.1% decrease from the year-ago quarter. The consensus mark for earnings has fallen by 2 cents in the past 30 days. BUD has a trailing four-quarter earnings surprise of 10.9%, on average. Primo Brands Corporation PRMB currently has an Earnings ESP of +1.38% and a Zacks Rank of 3. PRMB is anticipated to register growth in its top and bottom lines when it reports second-quarter 2025 results. The Zacks Consensus Estimate for Primo Brands' quarterly revenues is pegged at $1.8 billion, indicating a surge of 275.5% from the figure reported in the prior-year quarter. The consensus estimate for Primo Brands' bottom line has moved down by 2 cents in the past 30 days to 43 cents per share. This implies growth of 65.4% from the year-ago quarter's figure. PRMB has delivered an earnings beat of 3.5%, on average, in the trailing four quarters. Altria Group, Inc. MO currently has an Earnings ESP of +1.03% and a Zacks Rank of 3. MO is anticipated to register top-line decline and bottom-line growth when it reports second-quarter 2025 results. The Zacks Consensus Estimate for Altria Group revenues is pegged at $5.2 billion, indicating a decline of 1.7% from the figure reported in the year-ago quarter. The consensus estimate for Altria's earnings has increased a penny in the past seven days to $1.37 per share. The consensus estimate implies a decline of 4.6% from the year-ago quarter's figure. MO has delivered an earnings beat of 1.3%, on average, in the trailing four quarters. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Altria Group, Inc. (MO): Free Stock Analysis Report Anheuser-Busch InBev SA/NV (BUD): Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP): Free Stock Analysis Report Primo Brands Corporation (PRMB): Free Stock Analysis Report
Globe and Mail
11 minutes ago
- Globe and Mail
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
Danaher Corporation DHR is scheduled to release second-quarter 2025 results on July 22, before market open. The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates an increase of 1.6% from the year-ago quarter's figure. The consensus mark for earnings is pinned at $1.64 per share, which has remained steady in the past 30 days. The estimate indicates a decrease of 4.7% from the figure reported in the year-ago quarter. The company's bottom line surpassed the Zacks Consensus Estimate in three of the preceding four quarters while missing the mark in one, the average beat being 8.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Let's see how things have shaped up for Danaher this earnings season. Key Factors and Estimates for Q2 Weakness in Danaher's protein consumables, flow cytometry and lab automation solutions businesses, due to lower demand across academic and government end-markets, is likely to have hurt the Life Sciences segment's revenues in the second quarter. Also, sales decline in the filtration business due to soft demand in the energy-related end market is likely to have impacted the segment's performance. We expect the segment's revenues to decrease 3.4% from the year-ago quarter to $1.71 billion. DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. For the quarter under review, we anticipate SG&A expenses to be $1.55 billion, indicating a 5.8% increase from the year-earlier level. The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability. However, strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe and Southeast Asia, is expected to have aided the Biotechnology segment. The segment's performance is also likely to have benefited from solid momentum in the discovery and medical business. We expect the segment's revenues to increase 7% from the year-ago quarter to $1.83 billion. Solid momentum in the pathology and acute care diagnostics businesses is expected to drive the Diagnostics segment's results. We expect the segment's revenues to increase 1.1% from the year-ago quarter to $2.29 billion. Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped the company solve some pertinent healthcare challenges. Earnings Whispers Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below. Earnings ESP: DHR has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.64 per share. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Zacks Rank: DHR presently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Stocks to Consider Here are some companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2025 results on July 31. CVS Health's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 18.1%. Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2025 results on Aug. 6. Cencora's earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 6%. Amgen Inc. AMGN has an Earnings ESP of +0.07% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2025 results on Aug. 5. Amgen's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.3%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
